Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 16;23(3):189-95.
doi: 10.1128/CVI.00609-15.

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

Patricio L Acosta  1 , Mauricio T Caballero  2 , Fernando P Polack  3
Affiliations
Review

Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

Patricio L Acosta et al. Clin Vaccine Immunol. .

Abstract

In 1967, infants and toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus (RSV) experienced an enhanced form of RSV disease characterized by high fever, bronchopneumonia, and wheezing when they became infected with wild-type virus in the community. Hospitalizations were frequent, and two immunized toddlers died upon infection with wild-type RSV. The enhanced disease was initially characterized as a "peribronchiolar monocytic infiltration with some excess in eosinophils." Decades of research defined enhanced RSV disease (ERD) as the result of immunization with antigens not processed in the cytoplasm, resulting in a nonprotective antibody response and CD4(+) T helper priming in the absence of cytotoxic T lymphocytes. This response to vaccination led to a pathogenic Th2 memory response with eosinophil and immune complex deposition in the lungs after RSV infection. In recent years, the field of RSV experienced significant changes. Numerous vaccine candidates with novel designs and formulations are approaching clinical trials, defying our previous understanding of favorable parameters for ERD. This review provides a succinct analysis of these parameters and explores criteria for assessing the risk of ERD in new vaccine candidates.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Photomicrograph of lung section from BALB/c mouse with enhanced RSV disease. Hematoxylin and periodic acid-Schiff stain shows peribronchiolar, perialveolar, and perivascular inflammation with abundant mucus production.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hall CB. 2010. Respiratory syncytial virus in young children. Lancet 375:1500–1502. doi:10.1016/S0140-6736(10)60401-1. - DOI - PubMed
    1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545–1555. doi:10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed
    1. Monto AS, Sullivan KM. 1993. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect 110:145–160. - PMC - PubMed
    1. Denny FW, Clyde WA Jr. 1986. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr 108:635–646. doi:10.1016/S0022-3476(86)81034-4. - DOI - PubMed
    1. Gruber WC. 1995. Bronchiolitis: epidemiology, treatment, and prevention. Semin Pediatr Infect Dis 6:128–134. doi:10.1016/S1045-1870(05)80039-1. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances